Rhinopharma

Rhinopharma is a Canadian biopharmaceutical company focused on developing novel therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma. The company's lead candidate, RP-101, is an inhaled p38 mitogen-activated protein kinase (MAPK) inhibitor designed to reduce airway inflammation. Rhinopharma aimed to provide more effective treatments for patients who do not respond well to current standard-of-care therapies like corticosteroids. Based in Vancouver, the company was supported by venture capital firms including BC Advantage Funds and the Working Opportunity Fund. Although the company advanced its lead program into Phase 2 clinical trials, it appears to have ceased active operations in recent years.